Advertising Press Release Distribution |   Reality TV   |  Lifestyle Magazine  |  Kiev Plastic Surgery

Lazer MedSpa News

Everything you need to know about lasers​

Lazer MedSpa News
BeautyLaser Treatment

Female-Founded Personal Care Disruptors SOS and Rael Partner to Give Away 200,000 Free Tampons and Pads

Female-Founded Personal Care Disruptors SOS and Rael Partner to Give Away 200,000 Free Tampons and PadsThe companies have forged an exclusive partnership to provide free access to natural, sustainable, effective period products and reach consumers through interactive advertising content at SOS’ 100+ locations.

Female-Founded Personal Care Disruptors SOS and Rael Partner to Give Away 200,000 Free Tampons and Pads
SOS Machine

Rael advertising displayed on a SOS machine

BOSTON – October 25, 2022 – (Newswire.com)

SOS, the Boston-based company that is redefining wellness on the go through a fast-growing network of smart vending machines, is announcing its exclusive product partnership with Rael, the 360 holistic feminine and beauty company focused on clean period care, intimate care, and skincare. 

Together, the female-founded and -led brands are committing to give away 200,000 tampons and pads at all of SOS’ 100+ machines throughout the next year in an effort to increase access to essential personal care products in high-traffic public locations where people need them most. The partnership is backed by a six-figure investment from Rael and is the largest direct brand investment to date for SOS.

“Every woman has experienced a moment when she needed a tampon and one was nowhere to be found, a frustrating feeling only exacerbated when in a public space like a sporting arena or office building,” said Susanna Twarog, co-founder and co-CEO of SOS. “We believe that all people deserve access to period care products wherever, whenever, and our partnership with Rael helps us bring that mission to fruition as we make their organic, effective pads and tampons available for free in all of our machines.”

Easily recognizable by their curvy shape and sleek video touch screen, SOS machines offer a range of exceptional just-in-time personal care and wellness products to meet a variety of needs. Completely cardless and contactless for consumers, SOS machines also deliver targeted, interactive advertising and educational content when not in use. This digital component is a unique aspect of SOS machines and enables highly targeted brand-building and customer acquisition programs that help brands stand out in an increasingly competitive marketplace. As part of the partnership, Rael will have access to personalized marketing campaigns and valuable data capture information at all SOS locations. 

“In today’s competitive marketing landscape, it has become harder than ever for brands to cut through the noise and capture consumer attention,” said Robina Verbeek, co-founder and co-CEO of SOS. “SOS machines provide a unique opportunity for brands to meet consumers exactly where they are in their moment of need and offer an immediate solution with a top-quality product. That is the type of impact that resonates with consumers and generates brand loyalty. Pair that with our first-party data capture capabilities, and brands have valuable insight to build a loyal customer base.” 

“We are excited to launch this initiative with SOS to promote equitable access to feminine care products. Our mission has never been clearer, and through this partnership, we look forward to giving more people access to healthy, organic options in women’s wellness and hygiene,” said Sorah Park, Chief Marketing Officer of Rael. “We know there can be a real financial burden when accessing feminine hygiene products, especially organic, and Rael is committed to providing greater ease for those in need of clean, safe, and effective solutions through the high-traffic access points in urban cities where SOS machines featuring Rael can be found.”

Launched in 2020 by Susanna Twarog and Robina Verbeek, SOS has grown its footprint to include prominent placement at high-traffic areas including New York City’s iconic Rockefeller Center, top sporting venues like Fenway Park, FLA Live Arena and TIAA Bank Field, in addition to a variety of public spaces around Boston, including Boston Children’s Hospital, District Hall, Prudential Center, South Station, and more. 

For more information, visit www.worldofsos.com

###

About SOS

SOS is transforming wellness on the go through a network of smart vending machines that deliver just-in-time necessities where and when you need them most. Each machine offers modern, premium health and wellness products from brands such as Rael, Megababe, First Aid Beauty, Drybar, and more. The company’s design-first hardware features a large, engaging touchscreen and serves as a visually rich advertising and marketing platform. SOS currently has more than 100 locations spread across Massachusetts, Florida and New York. 

About Rael

Rael is made by women for all people who bleed. Founded by three Korean American women in Los Angeles, including CEO Yanghee Paik in 2017, Rael empowers women to make healthier choices for their bodies through its safe and high-performance personal care products accessible to women around the world. Thoughtfully designed with natural and sustainable materials, Rael’s products are manufactured with cutting-edge South Korean manufacturing technology to deliver the latest innovations in feminine and skin care, providing a 360° holistic solution for the modern woman. Rael products can be found at getrael.com, as well as major retailers including Amazon, Target, Walmart, CVS, and Walgreens. Rael is backed by Unilever Ventures, BAM Ventures, PGVC, Softbank Ventures Asia, and Atinum Partners among others.

Contact Information:

Amy Tatnall

amy@madeyoufeel.com

Press Release Service
by
Newswire.com

Original Source:

Female-Founded Personal Care Disruptors SOS and Rael Partner to Give Away 200,000 Free Tampons and Pads

Read More
Health

The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy

The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene TherapyVirtual workshop on Nov. 17-18 bridges the gap between critical stakeholders to pinpoint today’s challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.

The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
Be the Match

Be the Match

MINNEAPOLIS – October 24, 2022 – (Newswire.com)

The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International Blood and Marrow Transplant Research® (CIBMTR®), and the National Marrow Donor Program® (NMDP)/Be The Match®, brings key stakeholders together to identify ongoing needs and opportunities in cell and gene therapy for advocacy, measurement of value and impact and sustainability. The virtual workshop on Nov. 17-18, 2022, joins providers, payers, government agencies and industry members who will work together to define essential factors needed to create a sustainable cell and gene therapy ecosystem. 

“NMDP/Be The Match is proud to be one of the sponsors of this important forum that has interests for all key stakeholders across the ecosystem,” said Jeffery Auletta, M.D., Senior Vice President, Patient Outcomes and Experience, of NMDP/Be The Match, Chief Scientific Director, CIBMTR. “Our established relationships with a global network of transplant centers and cell and gene therapy developers uniquely position NMDP/Be The Match to bring these experts together to identify the needs and opportunities in this field for advocacy, measurement, and sustainability.”

Dr. Auletta will join industry and transplant center partners and other professionals to address the question, “Are Center-Specific Outcomes Possible for CAR T-cell Immunotherapy?” The participants will focus on the perspectives of the payer, data acquisition and analysis, and center perspectives in defining outcomes for CAR T cells. They will also discuss healthcare inequity, specifically barriers to access and their impact on cell therapy outcomes. The speakers will incorporate the evolving cell therapy landscape from industry collaboration to clinical trials and real-world treatment in their presentations and in a moderator-led roundtable with attendee participation. Visit the event website to register and see the complete schedule and list of presenters.

In addition to NMDP/Be The Match, the event co-hosts include:

The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional membership association of more than 3,000 physicians, investigators, and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. For more information about ASTCT, visit www.astct.org and follow us on Twitter, @ASTCT.

The CIBMTR, a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin, facilitates critical cellular therapy research through a clinical database of more than 600,000 patients from more than 350 centers worldwide, with a biospecimen repository of more than 195,000 samples. 

Background:

The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®—a collaboration with the Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.

Contact Information:

Phyllis Grabot

phyllis@clarityqst.com

Bonnie Quintanilla

bonnie@clarityqst.com

Press Release Service
by
Newswire.com

Original Source:

The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy

Read More
Health

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the USTest offers EoE patients a simple, clinically proven method to control their disease. “…Beyond thrilled to use this at Phoenix Children’s Hospital…” – Dr. Schroeder, Medical Director, Eosinophilic Disease Clinic, Phoenix Children’s Hospital

AURORA, Colo. – October 24, 2022 – (Newswire.com)

Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children’s Hospital of Colorado, performed the Esophageal String Test® (EST) on a patient in early September. The test will be offered regularly at the hospital.

The EST was also performed on patients in the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. 

I am now beyond thrilled to use this new esophageal surveillance technique at Phoenix Children’s and for my patients with eosinophilic gastrointestinal disorders. The EST is a game-changer for my patients who are looking for a less invasive and less expensive way to screen their disease activity,” said Dr. Shauna Schroeder, Medical Director for the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. She further stated “Having trained in Denver, I had experience using the EST as a research tool in patients with eosinophilic esophagitis. I am now able to more granularly adjust medications and diets improving the care of my patients with eosinophilic esophagitis.”

The Esophageal String Test® utilizes a simple collection device, the EnteroTracker®, to collect upper gastrointestinal samples from adults and children.  The samples are sent to an independent reference lab for analysis of disease activity. Several other clinics around the country are planning to offer the test soon.

About EnteroTrack 

EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

Contact Information:

Robin Shandas

CEO, Media and Investor Inquiries

robin.shandas@enterotrack.com

Brookelynn Stillwell

General Inquiries

brookelynn.stillwell@enterotrack.com

Press Release Service
by
Newswire.com

Original Source:

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US

Read More
Health

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

LAS VEGAS – October 24, 2022 – (Newswire.com)

Gb Sciences, Inc. (“GbS”; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS’ proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS’ proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company’s first non-cannabis formulations to advance in preclinical studies.

“We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations,” said Dr. Andrea Small-Howard, Gb Sciences’ President and Chief Science Officer. “This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs.”

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

grow@rosarium.work

Contact Information:

Madeleine Moench

madeleine@newswire.com

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Read More
Advertising Business Newspaper |   Miami News   |   Lifestyle Magazine  |   Fashion Magazine | Digital Newspaper Lifestyle Magazine | Woman Magazine Lifestyle News Politic News |   Miami News   |   Lifestyle Magazine |   Politics News   |   Lifestyle Magazine